Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of patient-derived resected lung NSCLC cells

ABSTRACT: Transcriptomic analysis of patient-derived resected lung NSCLC cells

PROVIDER: PRJNA941787 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23722632_1.fastq.gz	Fastqsanger.gz
	SRR23722632_2.fastq.gz	Fastqsanger.gz
	SRR23722633_1.fastq.gz	Fastqsanger.gz
	SRR23722633_2.fastq.gz	Fastqsanger.gz
	SRR23724982.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 2)

Project description:To identify genes encoding cell surface proteins that are preferentially expressed in NSCLC cells, CD45-CD31-EpCAM+ cells were purified by FACS from either tumor regions or unaffected regions in resected lung tissues from patients with NSCLC, then subjected to RNA sequencing analysis.

2024-08-05 | GSE226773 | GEO

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 1)

2024-08-05 | GSE226772 | GEO

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 2)

Project description:Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 2)

| PRJNA942052 | ENA

Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 1)

Project description:Transcriptomic analysis of patient-derived resected lung NSCLC cells (part 1)

| PRJNA942048 | ENA

Single cell RNA sequencing analysis of freshly resected non-small cell lung carcinoma (NSCLC) tissues

Project description:Lung cancer is the leading cause of cancer-related deaths world-wide. ~85% of lung carcinomas are non–small cell lung carcinoma (NSCLC). Tumor cell heterogeneity is very poorly defined. However, it is known to be important for tumor response to cancer therapy and cancer agressivenes. We subjected three NSCLC tumors resected from different patients to Drop-seq in order to 1) elucidate the capability of scRNA-seq analysis in identifying different tumor cell populations; and 2) ascertain the clinical value of the genes which distinguish cancer cells from other cells in the tissue. As anticipated, the tissue composition of independently collected samples varied. Despite deficient populations in some samples, both donor and patient samples contributed to the majority of cell populations. However, cancer cells were all patient-specific. These findings emphasize the utility of single cell gene expression data in identification of tumor cell populations. The collected data might be further used for predicting of drugs specific to the biology of activated pathways and patient outcome.

2020-12-19 | GSE148466 | GEO

Phosphoproteome of NSCLC patient–derived cells.

Project description:Phosphoproteome of anaplastic lymphoma kinase–positive non-small cell lung cancer (ALK+ NSCLC) patient–derived cells.

2024-11-19 | PXD050973 | JPOST Repository

Transcriptomic analysis of patient-derived resected lung NSCLC cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-08-04 | GSE226774 | GEO

Ago iCLIP of TLE patient resected hippocampus

Project description:Ago iCLIP of TLE patient resected hippocampus

| PRJNA884734 | ENA

Single cell RNA sequencing analysis of freshly resected non-small cell lung carcinoma (NSCLC) tissues

Project description:Single cell RNA sequencing analysis of freshly resected non-small cell lung carcinoma (NSCLC) tissues

| PRJNA624325 | ENA

Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies unique proteotypes associated with patient outcomes [HT12v4]

Project description:Non-small cell lung cancer (NSCLC) death rates exceed the next 3 prevalent cancers combined; however, most NSCLC tumors lack actionable mutations. Recent studies of NSCLC and other cancers revealed profound proteome remodelling with prognostic impact that is not fully predicted by DNA or RNA analyses. These revelations portend proteome-based cancer classification and treatment. This will require model systems that recapitulate tumor proteomes and phenotypes. A subset (~35%) of the most aggressive NSCLC can form a patient-derived xenograft (PDX). We generated 137 PDX models of aggressive NSCLC, which represent the histological, genome, transcriptome, and DNA methylation features and proteome remodelling of primary NSCLC. The models indicate 3 lung adenocarcinoma and 2 squamous cell carcinoma proteotypes that are associated with different patient outcomes, protein-phosphotyrosine profiles, candidate targets, and in adenocarcinoma, distinct stromal immune features. The PDX resource will foster proteome-directed stratification and development of new treatments for aggressive NSCLC.

2021-11-23 | GSE166997 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data